recently introduced a mechanistic agentbased cell model, with application to ductal carcinoma in situ (DCIS)-a precursor to invasive breast cancer. The work included the first patient-specific calibration method to use pathology data from a single time point, as might be expected in a presurgical biopsy. The key measurements included the proliferative index (PI: the percentage of cycling cells), the apoptotic index (AI: the percentage of cells apoptosing), the mean viable rim thickness T , the mean duct radius R duct , the mean nuclear radius R N , mean cell density ρ , and the cell confluence f (percentage of the viable rim occupied by cell mass).
The authors demonstrated the calibration for an individual patient with solid-type DCIS with comedonecrosis, and used the calibrated model to predict the patient's DCIS growth rate and pathology-mammography size correlations. While the model predictions were quantitatively consistent with literature reports for similar cases, the calibration over-predicted the patient's proliferative index (PI), underpredicted the cell density, and overpredicted the patient's viable rim size. The authors attributed the discrepancy in PI to the neglect of the post-mitotic G 1 phase in the calibration method (daughter cells stain positive for Ki-67 after mitosis as they continue to cycle and grow, then exit to G 0 ), while they concluded that approximating the viable rim as 100% confluent likely caused the discrepancies in the cell density and viable rim size.
We now present and demonstrate an improved calibration method that addresses these shortcomings. We find that the new calibration substantially improves the model match to the patient's PI, AI, ρ , and T measurements; this should make possible better quantitative model predictions of individual patients' tumor growth. In the interests of brevity, we only present the changes in the calibration. A MATLAB script is provided at MathCancer.org to help automate the calibration.
Population dynamics: Let PI 1 be the pre-mitotic cycling cells (S, G 2 , M, and possibly parts of G 1 , with duration τ 1 ), and let PI 2 be the cells in the post-mitotic G 1 phase (with duration τ 2 = τ G1 ). Let AI be as before, with duration τ A . Note that PI 1 + PI 2 = PI and τ 1 + τ 2 = τ P . PI 1 , PI 2 , and AI satisfy: 
As in , we assume a steady-state population dynamic and setṖI 1 ,ṖI 2 , andȦI equal to zero. Assuming we have measurements for AI, PI, τ A , τ 1 , and τ 2 , we must solve for PI 1 (or PI 2 ), α P , and α A . Eqn. 2 can be explicitly rewritten to solve for PI 1 by substituting PI 2 = PI − PI 1 . Hence:
Using this, we can solve for α P and α A :
The remainder is as in .
Cell geometry:
We do not have quantitative measurements of the patient's confluence, but we estimate f ∼ 0.90. We continue to set R N = 5.295 µm. If A is the mean cell cross-sectional area and R is the mean cell radius,
Next, we relate R to the quiescent cell radius R via the AI, PI 1 and PI 2 fractions from above:
where Vx is the mean cell volume in the x phenotypic state (x ∈ {P 1 , P 2 , A, Q}). For the model in ,
Using these, we directly solve for R and V , the equivalent radius and cell volume in the quiescent state Q. More detailed cell volume models (e.g., as in Mumenthaler et al. (2012) ) require adjusting these per-state mean volumes.
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, and λcore = λ b in the necrotic core. Define the length scales
and
in the viable rim and necrotic core, respectively, where L 0 (100 µm) is the viable oxygen diffusion length scale. Define the mean necrotic core radius R NC = R duct − T . After adjusting the oxygen equations from to use these uptake rates, solving analytically, and evaluating at the duct boundary, we find the updated oxygen boundary value σ B via:
The mean oxygen in the viable rim is obtained via:
Cell-cell mechanics: For the general case where f = 1, we determine the mean cell-cell spacing s in the confluent region by
The mechanics calibration continues as in with this altered mean cell-cell spacing in the confluent region.
Updated parameter values:
Using this updated calibration for the patient data presented in , the new patient-specific parameters are given in Table 1 
Comparison against the original calibration:
We simulated 45 days of growth using the updated parameter values above. As in , we post-processed the original and new simulations in 1-hour increments to calculate the simulated PI, AI, cell density, and viable rim thickness. Further postprocessing details and open source C++ code can be found in and at http://MathCancer.org/JTB DCIS 2012/.
For each simulation, we calculated the mean and standard deviation of these statistics from T 150 to 45 days. (T 150 is the first time the "cropped" portion of the viable rim has at least 150 cells. This helps us to more directly compare the simulations while (1) eliminating early transient dynamics and (2) including at least 15 days of simulated data as in .) For the original simulation in 
In Fig. 1 , we plot the means (triangles) of PI, AI, density, and viable rim size for the patient (red bars), original parameter values (blue), and new parameter values (black). The bars represent ± one standard deviation of each quantity, to give a sense of the variability of each measurement. Our new calibration (black bars) is much more successful than our old calibration (blue bars) at matching the patient's mean PI, density, and viable rim size. See Table 2 . Table 2 Verification of the patient-specific calibration: Comparison of the patient (second column) and computed (third and fourth columns) mean and standard deviation for the proliferative index, apoptotic index, cell density, and viable rim thickness. All computed quantities are within the range of patient variation; the new calibration (third column) is substantially better than the original (fourth column).
Final thoughts: As suggested in , agentbased model calibration to individual patients can be substantially improved by accounting for (1) post-mitotic Ki-67 positive cells in the G 1 phase, and (2) the viable rim cell confluence. In our tests, the new calibration better matches the patient's PI, density, and viable rim size. In continuing work, we are applying this new calibration to a larger number of patients for a case-by-case validation of personalized predictions of cancer progression.
